206. 脆弱X症候群 Fragile X syndrome Clinical trials / Disease details
臨床試験数 : 108 / 薬物数 : 91 - (DrugBank : 36) / 標的遺伝子数 : 52 - 標的パスウェイ数 : 77
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT05301361 (ClinicalTrials.gov) | February 1, 2023 | 8/3/2022 | Sensitivity of the NIH Toolbox to Stimulant Treatment in Intellectual Disabilities | Sensitivity of the NIH Toolbox Cognition Battery to Stimulant Treatment in Intellectual Disabilities | Intellectual Disability;Fragile X Syndrome;Down Syndrome;Attention Deficit Hyperactivity Disorder | Drug: Methylphenidate Oral Solution | University of California, Davis | NULL | Recruiting | 6 Years | 17 Years | All | 68 | Phase 1 | United States |
2 | NCT00768820 (ClinicalTrials.gov) | May 2001 | 7/10/2008 | The Psychiatric and Cognitive Phenotypes in Velocardiofacial Syndrome | The Psychiatric and Cognitive Phenotypes in Velocardiofacial Syndrome (VCFS), Williams Syndrome (WS)and Fragile X Syndrome Characterization, Treatment and Examining the Connection to Developmental and Molecular Factors | Velocardiofacial Syndrome;Williams Syndrome;Fragile X Syndrome | Drug: methylphenidate, fluoxetin, risperidone | The Chaim Sheba Medical Center | NULL | Recruiting | N/A | N/A | All | 400 | Phase 4 | Israel |